Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC Services Private Limited | PRODUCT CODE: 1127734

Cover Image

PUBLISHER: IMARC Services Private Limited | PRODUCT CODE: 1127734

Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

PUBLISHED:
PAGES: 105 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 2499
PDF (5 User License)
USD 3499
PDF (Corporate License)
USD 4499

Add to Cart

The global oncology biosimilars market size reached US$ 2.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 12 Billion by 2027, exhibiting a growth rate (CAGR) of 22.78% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on drug type, cancer type and distribution channel.

Breakup by Drug Type:

  • Monoclonal Antibody
  • Immunomodulators
  • G-CSF
  • Hematopoietic Agents
  • Others

Breakup by Cancer Type:

  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Breast Cancer
  • Kidney Cancer
  • Stomach Cancer
  • Brain Cancer
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • Europe
  • Asia Pacific
  • North America
  • Middle East and Africa
  • Latin America

Competitive Landscape:

  • The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

Key Questions Answered in This Report:

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology biosimilars industry?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?
Product Code: SR1022A03_Report

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Biosimilars Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Cancer Type
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibody
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunomodulators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 G-CSF
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Hematopoietic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Colorectal Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cervical Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Breast Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Stomach Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Brain Cancer
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Europe
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 North America
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocon Limited
    • 14.3.2 Celltrion Inc.
    • 14.3.3 Dr. Reddy's Laboratories Ltd.
    • 14.3.4 Intas Pharmaceuticals Ltd.
    • 14.3.5 STADA Arzneimittel AG
    • 14.3.6 Pfizer Inc.
    • 14.3.7 Apotex Inc.
    • 14.3.8 Teva Pharmaceutical Industries Ltd.
    • 14.3.9 Sandoz International GmbH
    • 14.3.10 BIOCAD Biotechnology Company
    • 14.3.11 Mylan N.V.
    • 14.3.12 F. Hoffmann-La Roche AG
Product Code: SR1022A03_Report

List of Figures

  • Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2021
  • Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2021
  • Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2021
  • Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2021
  • Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
  • Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
  • Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2016 & 2021
  • Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2022-2027
  • Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2016 & 2021
  • Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2022-2027
  • Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2016 & 2021
  • Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2022-2027
  • Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2016 & 2021
  • Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2022-2027
  • Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2022-2027

List of Tables

  • Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2022-2027
  • Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2022-2027
  • Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
  • Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 6: Global: Oncology Biosimilars Market Structure
  • Table 7: Global: Oncology Biosimilars Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!